Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Calliditas
Biotech
Calliditas' rethought liver disease trial hits primary endpoint
The biotecch only saw a positive trend on liver stiffness and reported a higher rate of dropouts on the drug.
Nick Paul Taylor
Jul 26, 2024 5:32am
Calliditas' cancer trial misses primary goal, hits on survival
May 7, 2024 6:39am
Alnylam closes in on phase 3 launch for Regeneron-partnered med
Aug 29, 2022 12:46pm
Alnylam stays on Calliditas' heels, passing a phase 2 checkpoint
Jun 9, 2022 10:21am